幽门螺杆菌对左氧氟沙星耐药的研究进展

Levofloxacin for Helicobacter pylori infection: Drug resistance and safety

Helicobacter pylori (H. pylori) is an important cause of chronic gastritis and peptic ulcer, closely correlates with mucosa-associated lymphoid tissue (MALT), and is a risk factor for gastric cancer. The constantly increasing rate of resistance of H. pylori to antibiotics is the main reason for failure of H. pylori eradication therapy. How to increase the H. pylori eradication rate has become the focus of current research. Current concepts in treatment of H. pylori infection, including the Maastricht Ⅲ consensus report and Chinese consensus report in recent years, have recommended levofloxacin as a first-line or remedial therapy, and good therapeutic effects have been achieved; however, the wide use of levofloxacin has led to an increase in drug resistant strains of H. pylori. Investigation of the mechanism behind levofloxacin resistance and the security of levofloxacin has important significance to guide the clinical medication. This paper reviews the role and mechanisms of levofloxacin in H. pylori eradication, levofloxacin resistance and related molecular mechanisms, and safety of levofloxacin in the management of H. pylori infection.